eligible ages (years): 18.0-999.0,  All  Vaginitis Dyspareunia Breast Neoplasms Histologically or cytologically confirmed breast cancer (any stage) Currently be using an aromatase inhibitor (anastrazole, exemestane or letrozole) for primary or adjuvant breast cancer treatment Must have complaints of vaginal itching, vaginal dryness and/or dyspareunia Not undergoing active chemotherapeutic or radiotherapeutic treatment Age >18 years Life expectancy of greater than 2 months CALGB (ZUBROD) performance status <3 Post-menopausal defined by absence of menses for at least 12 months and/or an FSH >25. Not post-menopausal as a function of medications intended to suppress ovarian function, such as gonadotropin releasing hormone agonists. Surgically post-menopausal subject eligible The effects of topical testosterone cream on the developing human fetus at the recommended therapeutic dose are unknown. For this study only post-menopausal women are included and all women of child-bearing potential are excluded. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately  Patients who have not recovered from adverse events due to chemotherapeutic agents administered more than 4 weeks earlier History of allergic reactions attributed to compounds of similar chemical or biologic composition to testosterone or the emollient delivery cream used in the study Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements Pregnant women and women who are breast-feeding are excluded from this study because it is limited to post-menopausal women


A 62-year-old man sees a neurologist for progressive memory loss and jerking movements of the lower extremities. Neurologic examination confirms severe cognitive deficits and memory dysfunction. An electroencephalogram shows generalized periodic sharp waves. Neuroimaging studies show moderately advanced cerebral atrophy. A cortical biopsy shows diffuse vacuolar changes of the gray matter with reactive astrocytosis but no inflammatory infiltration.

eligible ages (years): 18.0-999.0,  All  Shock, Septic patient (or representative) received the information notice patient has hemodynamic insufficiency of non-traumatic or cardiogenic origin associated with severe sepsis (treated with Noradrenalin) and organ dysfunction, hypoperfusion or hypotension body temperature > 38.3°C or < 36°C heart rate > 90 bpm Tachypnea > 20 C/min or PaCO2 < 32 mmHg or mechanical ventilation leukocytes > 12000 µL-1 ou < 4000 µL-1 ou > 10% immature forms oliguria < 0.5 ml/kg/h for at least 2 hours abrupt alteration (24 h) of conscienceness thrombocytopenia < 100 000 G/L or disseminated intravascular coagulation mottled skin and / or capillary refill time> 3 sec  patient is dying or limitation or cessation of active treatment patient is already included in another trial patient or family refusal patient not affiliated with a social security system


eligible ages (years): 50.0-80.0,  All  Parkinson's Disease Medical clearance to perform an exercise tolerance test and training program A diagnosis of PD at stage 2 on the Hoehn and Yahr scale  A neurological condition other than PD/ Anyone who is currently taking any vitamin supplementation Smokers Anyone currently engaged in weight training


eligible ages (years): 0.0-999.0,  All  Alzheimer's Disease Gait Apraxia Impaired Cognition All elderly patients from the University Memory Center of Angers University Hospital Able to walk without any walking aid on 15 meters Mini-Mental Status Examination score > 10 Being affiliated to a social security regime  Mini-Mental Status Examination score ≤ 10 Subject suffering from pre-existing impellent disturbances History of cerebrovascular accident or other cerebro-spinal pathology Poor workmanship of the written or oral French language Use of walking aid such as walking frame with wheels or tricycle Acute medical or surgical disease in the past 3 months Refusal to participate (or trustworthy person) Near visual acuity < 2/10


eligible ages (years): 30.0-80.0,  All  Stroke for patients wth stroke Age 40-80 years sustained a single stroke between 3-24 months prio t study leading to upper limb paresis have at least Stage 3/7 arm control (mild to moderate motor deficits) on the Chedoke-McMaster Scale <81 yrs old to minimize confounding effects of age-related changes in sensorimotor functions  for patients wth stroke other neurological or orthopaedic problems that may interfere with interpretation of results significant deficits in attention, constructional skills, neglect and apraxia shoulder subluxation, arm pain lack of endurance as judged by a physician undergoing other therapy, surgery or medical procedures within the study period for healthy control subjects Age 40-80 years for control subjects any neurological or orthopaedic problems that may interfere with interpretation of results


eligible ages (years): 0.0-999.0,  All  Mumps Subjects with upper or lower limb spasticity Subjects must use botulinum injection for the first time


eligible ages (years): 55.0-95.0,  All  Dementia, Alzheimer Type Non-institutionalized patients with a diagnosis of Alzheimer's disease as defined by Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) with symptoms of delusions or hallucinations, which have been present, at least intermittently for one month or longer Mini Mental State Examination (MMSE) score of 6 to 24 points Patients capable of self locomotion or locomotion with the aid of an assistive device Patients with an identified caregiver or proxy For Extension Phase Eligible patients were males and females who had completed the 10-week Acute Phase in either treatment group; had a Week 10 Total Score of ≥ 6 on the NPI; and were, in the judgment of the investigator, deemed suitable for participation in the long-term trial Treatment beyond 140 weeks All subjects who completed the extension phase of CN138-006 in any French Investigational Site may be considered eligible for entry until they are no longer receiving clinical benefit, per the investigator's judgment  Patients with an Axis I (DSM IV) diagnosis of delirium amnestic disorders bipolar disorder schizophrenia or schizoaffective disorder mood disorder with psychotic features Patients with reversible causes of dementia Patients with psychotic symptoms continuously present since prior to the onset of the symptoms of dementia Patients with psychotic symptoms that are better accounted for by another general medical condition or by direct physiological effects of a substance Patients with a current major depressive episode with psychotic symptoms of hallucinations or delusions


eligible ages (years): 18.0-35.0,  All  Graft Versus Host Disease (GVHD) Acute Myocardial Infarction (AMI) Age 18 to 35 years Willingness to provide written informed consent  Presence of risk factors for or clinical evidence of Human immunodeficiency virus (type 1 and 2), Hepatitis B, Hepatitis C, Human T-lymphotrophic virus (type I and II), Human transmissible spongiform encephalopathy (including Creutzfeldt-Jakob disease) treponema pallidum Presence of communicable disease risk associated with xenotransplantation Test positive for Human immunodeficiency virus (type 1 and 2), Hepatitis B, Hepatitis C, Human T-lymphotrophic virus (type I and II), cytomegalovirus (CVM), West Nile Virus, treponema pallidum Use of investigational drug within 30 days or 5 half lives which ever is longer. Use of investigational implanted device History of malignancy Pregnancy In the opinion of the hematologist or the investigator, a condition that compromises the ability of the donor to safely provide BM donation


eligible ages (years): 0.0-999.0,  All  Menopause Postmenopausal Vaginal Atrophy Atrophic vaginitis due to estrogen deficiency Post-menopausal


eligible ages (years): 40.0-85.0,  All  Parkinson's Disease Mild Cognitive Impairment Participants must be experiencing symptoms of mild cognitive impairment; this will be determined by study personnel Participants must be on a sable medication regimen for 2 months prior to starting the study (necessary dose adjustments during the study are acceptable) Participants are capable of giving informed consent supported by not meeting Parkinson's disease Dementia criteria; this will be determined by study personnel  Active suicide ideation Weighing less than 100 lbs (45 kgs) History of Deep Brain Stimulation surgery Diagnosis of Dementia Taking certain types of medications may be an  this will be reviewed with all potential participants Females that are pregnant, planning to become pregnant, or are breastfeeding will not be included in the study. Females of childbearing potential will need to verify that they are not pregnant by a negative urine pregnancy test


eligible ages (years): 50.0-999.0,  All  Alzheimer's Disease for AD cases Diagnosis of probable AD, defined according to the criteria51 Light to moderate severity of the disease, defined by a MMSE score >10 (global evaluation of cognition) Patient aged 50 years or more Patient benefiting from social insurance for controls Absence of suspicion of dementia, based on normal performance according to age and educational level at neuropsychological testing defined as Free recall ≥17 and total recall ≥40 for the Free and Cued Selective Reminding Test (Grober and Buschke test 52) MMSE ≥ norm for age and educational level (defined by mean SD) Isaac's set test ≥ norm for age and educational level (defined by mean  for all patients  History of Parkinson's disease or other neurodegenerative disorder History of Horton's disease History of inflammatory neuropathies (in particular Devic's disease, multiple sclerosis) History of vascular ischemic neuropathies and chronic intracranial hypertension History of pituitary tumors Presence of diseases (systemic and/or ocular diseases) or behavioural or cognitive symptoms incompatible with eye examination Known diabetes Person under tutorship or curatorship, person unable to express consent Additional


eligible ages (years): 18.0-999.0,  All  Differentiated Thyroid Cancer Age over 18 years Patient has thyroid cancer Patient is judged as being capable of understanding the information sheet and of giving informed consent (Mental Capacity Act 2005) Responsible clinician is approached and is happy for the patient to be included in the study  Age of less than 18 years Patient has additional risk infections (HIV, Hep B/C) Patient is involved in other medicinal or treatment based clinical trial at the time of recruitment or in the previous 4 months


eligible ages (years): 18.0-999.0,  All  Breast Cancer newly diagnosed breast cancer no metastasis detected operation for breast cancer female patient unilateral breast cancer informed consent given age min. 18 yrs  metastasis of breast cancer bilateral breast cancer other cancer within the last 5yrs


eligible ages (years): 18.0-55.0,  All  Multiple Sclerosis, Relapsing-remitting Enrolled into the 2-year, double-blind, placebo-controlled ASA study and entered 3 year extension study MRI was performed on all patients using a 1.5 T magnet  MRI images unable to be processed All 5 MRI time points not collected


eligible ages (years): 40.0-70.0,  All  Arthrosis of the Knee The participants of the study are patients that have been scheduled for a primary TKA using the usual indications for TKA at the Department of Planned Elective Surgery Z, Gentofte Hospital Severe osteoarthrosis of the knee with indication for a TKA Age between 40 and 70 years  Diseases affecting the bone metabolism (osteoporosis, Pagets disease, hyperparathyreoidism etc.) Patients estimated not to be able to understand the "Information to patients" papers or do not want to participate in the study


eligible ages (years): 18.0-80.0,  All  Knee Arthritis patients waiting for knee replacement  neurologic disease


eligible ages (years): 8.0-21.0,  All  Brain Structural Connectivity Cognitive Function Ages 8-21 without current and past history of any psychiatric disorder and autistic symptoms  Current symptoms or lifetime history of DSM-IV-TR diagnosis of attention-deficit/hyperactivity disorder, pervasive developmental disorder, schizophrenia, schizoaffective disorder, delusional disorder, other psychotic disorder, organic psychosis, bipolar disorder, depression, severe anxiety disorders or substance use With neurodegenerative disorder, epilepsy, involuntary movement disorder, congenital metabolic disorder, brain tumor, history of severe head trauma, and history of craniotomy With major systemic disease Full-scale IQ < 80


eligible ages (years): 65.0-89.0,  All  Mild Cognitive Impairment Dementia Memory Disorders Age between 65 and 89 Successful completion of primary school MCI, as Mini Mental State Examination score between 20 and 27 and confirmation through neuropsychological examination by a specialist, according to current guidelines  Moderate/severe dementia Clinical signs of depressive disorder or other primary psychiatric disorders Neoplastic diseases Neurologic or musculoskeletal deficits barring neuropsychological examination or physical or cognitive training Severe heart disease End stage renal disease (eGFR<35 ml/min(1.73 m2) Severe chronic obstructive pulmonary disease (COPD) and/or respiratory failure Complicated or decompensated diabetes Overt peripheral artery disease Any inability to successfully complete a brain magnetic resonance scan


eligible ages (years): 18.0-90.0,  All  Ischemic Stroke Involving Corticospinal Tract. Patients of 18 to 90 years old Subcortical stroke Achievement of the internal capsule, according to MRI Ability to perform MRI within 10 days after the onset of symptoms NIHSS over or equal 2 and < 20 Rankin Score over or equal 1 and ≤ 5 Written informed consent after information about the protocol, from patients or reliable person if patient is in incapacity to sign Affiliation to a social security scheme  Pregnant or nursing women Other cerebral lesion, concomitant or preexisting Concomitant disease causing unfavorable prognosis within 3 months after pre-existing psychiatric illness Alcoholism or other chronic intoxication Cortical localization of the infarction Patient in a coma, who cannot be examined and evaluated Patient intubated, ventilated, sedated Cerebral hemorrhage, intra-parenchymal and / or subarachnoid Persons protected by law (guardianship, curators and judicial protection)


eligible ages (years): 40.0-79.0,  All  Lower Limb Spasticity After Stroke patients with lower limb spasticity after stroke duration more than 6 months Modified Ashworth Scale of ankle joint more than 2  patients with previous botulinum toxin injections to lower limbs patients with serious hepatic, renal or cardiac dysfunction patients with respiratory failure patients who cannot understand the instructions


eligible ages (years): 0.0-999.0,  All  Breast Neoplasms Newly diagnosis of breast cancer for which surgical intervention is planned  patients received neoadjuvant chemotherapy before breast surgery


eligible ages (years): 30.0-999.0,  All  Atrial Fibrillation Heart Failure Stroke Myocardial Infarction Patients with a coded diagnosis for atrial fibrillation in their primary or secondary care record Patients in GPRD practices which are deemed "up to standard" by GPRD Patients whose records are deemed "acceptable" by GPRD and contain at least one year of data Patients whose age and sex, as recorded in GPRD is the same as that recorded in HES  A diagnosis of heart failure, stroke, or myocardial infarction occurring before diagnosis of atrial fibrillation


eligible ages (years): 65.0-85.0,  All  Disturbance; Balance, Labyrinth Parkinson´s Disease Elderly The patient is able to provide informed consent Definitive Idiopathic Parkinson's Disease as diagnosed by a Neurologist Hoehn and Yahr Stage 1-3 Able to ambulate without an assistive device On stable doses of Parkinson's medications prior to study onset  Mini Mental Status Exam (MMSE) < 24 Change in Parkinson's medications in the duration of study Uncontrolled orthostasis Symptomatic coronary artery disease Fracture of lower limb prior to study onset Other neurologic diagnosis Physical therapy before and during to study duration Significant camptocormia Any medical condition which the physician investigator determines would compromise the safety of exercise program for the subject


eligible ages (years): 50.0-999.0,  All  Sleep Disordered Breathing Alzheimer's Disease Male and female subjects with normal cognition and >50 years of age will be enrolled. Younger subjects are not included as the risk for cognitive impairment is too low. Moreover, by selecting this age-range we minimize the possibility of including early-onset genetic forms of neurodegenerative diseases such as Alzheimer's disease and Frontotemporal Dementia Normal subjects will be within normal limits on neurological and psychiatric examinations. All subjects enrolled will have both a Clinical Dementia Rating = 0 and Global Deterioration Scale < 3 All subjects will have had a minimum of 12 years education.The education restriction reduces performance variance on cognitive test measures and improves the sensitivity for detecting pathology and disease progression using the robust norms available at NYU School of Medicine All subjects will have an informed family member or life partner interviewed to confirm the reliability of the subject interview. All subjects will agree to the MRI imaging, the lumbar puncture, apolipoprotein E (ApoE) genotyping and DNA banking  Diagnosis of any brain disease or MRI evidence of brain damage including significant trauma, hydrocephalus, seizures, mental retardation or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders). Persons with silent cortical infarcts are excluded. Subcortical infarcts and white matter lesions are not exclusions History of brain tumor Any radiation or chemotherapy anywhere in the body in the past 3-years Significant history of alcoholism or drug abuse History of psychiatric illness (e.g., schizophrenia, mania, PTSD, or life long history of major depression) Hamilton Depression Scale >16 only with history of life long depressive episodes. Otherwise not excluded Evidence of clinically relevant and uncontrolled cardiac, pulmonary, or hypothyroid or hematological conditions. Insulin dependent diabetes and/or history or treated hypertension are not an exclusion. Normal subjects with current levels of HbA1c >5.9% or diabetics >7.0% (American Diabetes Association, 2010) and/or current blood pressure levels >140/90 mm Hg (JNC on Prevention, Detection, Evaluation and Treatment of High Blood Pressure, 2003) will be advised to seek referral Physical impairment of such severity as to adversely affect the validity of psychological testing Hostility or refusal to cooperate Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging


eligible ages (years): 2.0-17.0,  All  Cerebral Palsy Spasticity Female or male subject of 2 to 17 years of age (inclusive) Uni or bilateral Cerebral Palsy (CP) with clinical need for injections with NT 201 for the treatment of upper limb (UL) spasticity at least unilaterally Ashworth Scale (AS) score in the main clinical target patterns in this study Flexed elbow: AS≥2 in elbow flexors (at least unilaterally). and/or Flexed Wrist: AS≥2 in wrist flexors (at least unilaterally) Clinical need according to the judgment of the investigator in one out of five treatment combinations (A-E, as shown below). AS score must be ≥2 for each target pattern chosen for injection at the Baseline Injection Visit V2 A. UL(s) treatment only (GMFCS I-V) A1) Unilateral treatment of UL spasticity with 8 U/kg BW NT 201 (maximum of 200 U) for At least one of the main clinical target patterns flexed elbow (4 U/kg BW) and/or flexed wrist (2 U/kg BW)  Pre-treated (non-naïve) subjects must not have received BoNT treatment within the last 16 weeks prior to study treatment at V2 in any indication


eligible ages (years): 18.0-999.0,  All  Lower Limb Spasticity Men or women age 18 years and above Post-stroke lower-limb spasticity Prior agreement with the patient to inject BoNT-A If previously treated with BoNT-A, (at least 3 months interval between last injection and inclusion) Therapeutic goals agreed jointly with the patient Functional Ambulation Classification (FAC) score 2-5 Capacity to comply with the protocol Written informed consent  Documented positive antigenicity to botulinum toxin Neuromuscular disease Use of medications that interfere with neuromuscular transmission Severe muscle atrophy in any muscle to be injected Any other indication that might interfere with rehabilitation or the evaluation of results Any non-stroke spasticity diagnosis Pregnancy or nursing mothers Previous participation in any study using Goal Attainment Scale (GAS)


eligible ages (years): 65.0-999.0,  All  Postoperative Cognitive Dysfunction Delirium Dementia Age ≥ 65 years Elective major surgery Planned general anesthesia  Cardiac surgery Neurosurgery including carotid endarterectomy Preoperative Mini Mental State (MMS) Examination Score < 24 Previous pathological neuroimaging (if available) History of cerebral or cerebrovascular pathology Chronic use of psychiatric medication Alcohol or substance abuse A history of chronic pain unrelated to the planned surgery Any contraindication for MRI (e.g. pacemakers and other MR-incompatible metal implants) Claustrophobia


eligible ages (years): 18.0-999.0,  All  Induced Pluripotent Stem Cells OR THIRD PARTY (ALLOGENEIC CELLS, AND Subjects who meet ALL of the following will be considered for enrollment into this study Be greater than or equal to 18 years of age, as of the date of enrollment. There is no upper age limit for donor enrollment Able to provide informed consent Meets the donation requirements established by AABB and FDA for allogeneic or autologous use with the exception of hemoglobin/hematocrit  Subjects who meet ANY of the following will be excluded from participation in this study as a third party donor or research volunteer Medical history that includes any of the following, as per AABB or FDA requirements for allogeneic use Thrombocytopenia or other blood dyscrasias Bleeding diathesis Antibiotic use within the prior 48 hours History of cancer History of exposure to transfusion transmitted diseases including HIV and hepatitis B and C as defined by the Standards for Blood Banking and Transfusion Services, AABB Travel to an area where malaria is endemic as defined by the CDC (www.cdc.gov/travel) At risk for the possible transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) as described in the FDA Guidance for Industry, January 9, 2002, Revised Preventive Measures to Reduce the Possible Risk of Transfusion of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products Febr le (temperature > 38 (Infinite)C)


eligible ages (years): 18.0-999.0,  All  Gaucher Disease Type 1 Age: >18 Gaucher disease type 1 Able to undergo a DEXA test  Minors


eligible ages (years): 18.0-999.0,  All  Amyotrophic Lateral Sclerosis (ALS) Patients ≥18 years of age, diagnosed with ALS (<2 months before inclusion) according to Airlie House : definite, probable, or probable laboratory supported Time between first symptoms and diagnosis less than 18 months Sporadic or familial cases Patient agreement to be followed in a given ALS centre during the duration of the study Patients with a loss of at least 1 point in 3 items of the rating scale or with a loss of at least 2 points in 2 items of the rating scale Patients who signed the informed consent form  Associated dementia or inability to understand the requirements of the protocol No helper ONS already begun Artificial nutrition: enteral or parenteral nutrition Known hypersensitivity to components of ONS Absence of treatment with Riluzole (RILUTEK®) Patient under guardianship or curatorship Participation in another research protocol


eligible ages (years): 30.0-75.0,  All  Stroke Paresis Motor deficits of the upper limb after a first ever stroke A minimum punctuation of 11 in the subtest from the Motricity Index and Trunk Control Test which evaluates grip and pinch Less than 6 months from stroke Age between 30 and 75 years Right-handed  Inability to speak and understand the Spanish or Catalan language Major cognitive impairment affecting comprehension Neurological or psychiatric co-morbidity Substance abuse Formal musical education (i.e. professional musicians) Metallic implants incompatible with neuroimaging assessment Withdrawal from the study Voluntary withdrawal of consent A new episode of stroke during the participation in the study


eligible ages (years): 0.0-999.0,  All  Dementia Paratonia Severe cognitive impairment (complete dependency in all activities of daily living (ADLs) Diagnosis of Alzheimer's disease, vascular dementia,or frontotemporal dementia Score> 3 on the paratonic assessment instrument, with paratonic rigidity in an arm(s) interfering in the provision of care  Alternate etiologies for increased tone Botulinum toxin 6 months preceding the study


eligible ages (years): 18.0-80.0,  All  Spasticity Men and women ≥ 18-80 years Poststroke limb spasticity Patients who have suffered a stroke in the previous 6 months Treatment goal has been previously agreed with the patient or their legal representative Patients with clinically significant poststroke upper/lower limb spasticity, in whom it has been decided to perform multidisciplinary treatment with BoNT-A + rehabilitation No previous treatment with BoNT-A Patient is able to follow the protocol Written informed consent  Neuromuscular disease Use of drugs that interfere with neuromuscular transmission Any other condition that could interfere with rehabilitation or evaluation of the results Diagnosis of spasticity not associated with stroke Pregnant or nursing mothers Prior participation in any other study in the 6 months before study entry


eligible ages (years): 65.0-999.0,  All  Major Depressive Disorder Current DSM-IV diagnosis of MDD, unipolar type, without psychotic features and 6 weeks minimum duration of current depressive episode Moderate severity of depression using the Hamilton Depression Rating Scale (HDRS > 20) English speaking, male or female 65 years of age or older Good general health Able to give informed consent  Antidepressant use or psychotherapy within the past 6 weeks or electroconvulsive therapy within the past 6 months Recent history (<6 months) of substance or alcohol abuse or dependence (DSM-IV criteria) Use of cognitive enhancing medications Current diagnosis of Post-Traumatic Stress Disorder or other Axis 1 psychiatric disorder Neurological diseases (e.g., Parkinson's disease, epilepsy, cortical stroke, Alzheimer's disease, traumatic brain injury) or dementia History of surgical procedures affecting study outcomes Contraindications for MR exam, i.e., no claustrophobia, no paramagnetic metal implants, able to fit in the MRI machine comfortably (BMI ≤ 38) Acute or uncontrolled medical illness or medication use impacting cognitive function


eligible ages (years): 18.0-999.0,  All  Parkinson's Disease Idiopathic Parkinson's Disease with bradykinesia and at least two of the following signs; resting tremor, rigidity, and asymmetry Despite optimal pharmacological treatment, at least one of the following symptoms: severe response fluctuations, dyskinesias, painful dystonia or bradykinesia A life expectancy of at least two years  Age below 18 years Previous PD-neurosurgery (e.g., DBS, pallidotomy, thalamotomy) Previous CLI (through a PEG-tube or Nasal Jejuna| tube) Hoehn and Yahr stage 5 at the best moment during the day Other severely disabling disease Dementia or signs of severe cognitive impairment Psychosis Current depression Contraindications for DBS surgery, such as a physical disorder making surgery hazardous Contraindications for PEG surgery such as interposed organs, ascites and oesophagogastric varices, or for Duodopa


eligible ages (years): 18.0-999.0,  All  Leukoencephalopathy diagnosis of glioma (stage 3 to 4) both genders age > 18 years treatment by radiotherapy and chemotherapy clinical monitoring post radiotherapy in Neurology Department, Pitié-Salpêtrière University Hospital and in the radiotherapy department of the Paul Strauss Institute  other neurological tumors and brain metastases psychiatric severe illness, including severe depression


eligible ages (years): 35.0-999.0,  All  HIV - Human Immunodeficiency Virus Cognitive Impairment age 35 years or older HIV infection for at least 1 year able to communicate in English or French capable of providing informed consent easy access to the internet EEG and MRI compatible  presence of dementia life expectancy < 3 y other neurological disorder including active opportunistic CNS infection psychotic disorder current substance dependence or abuse; and Hepatitis C requiring interferon therapy during the study period


eligible ages (years): 18.0-999.0,  All  Cancer Rectal Cancer High-risk patients with biopsy proven rectal adenocarcinoma who will undergo long-course chemoradiotherapy (CRT) and who are potentially eligible for curative surgery Patients who have persistently (i.e. in baseline and post-treatment MRI) mrEMVI positive (with superior rectal vein invasion) or mrEMVI negative tumours Patients aged over 18 years Negative (on CT) for metastatic disease  Under 18 years of age Patients with any metastatic disease Patients with a synchronous second malignancy


eligible ages (years): 18.0-55.0,  All  Multiple Sclerosis 55 inclusive years of age at the time of informed consent Diagnosis of relapsing multiple sclerosis as defined by the 2010 revised McDonald Currently taking Tysabri  Systemic steroid users comorbidities that could confound MRI outcomes


eligible ages (years): 35.0-75.0,  All  Parkinson Disease Dementia Age at the time of enrollment: 35 years Diagnosis of idiopathic PD with probable Parkinson's disease dementia (PDD) as defined by the MDS consensus guidelines (Emre et al., 2007) Mild to moderately severe dementia as defined by a Mini-Mental State Examination (MMSE) score of 10 to 24 Duration of bilateral idiopathic PD: ≥5 years of motor symptoms Severity of bilateral idiopathic PD in the meds off state: modified Hoehn and Yahr stage ≥2 UPDRS subset III score of ≥30 in the meds off, stim off state Levodopa must improve PD symptoms by ≥30% in a levodopa challenge test, as measured by UPDRS subset III score PDD with a symptom onset at least 2 years after first symptoms of PD Be willing and able to comply with all visits and study related procedures (e.g., using the remote control, charging systems and completing the motor diary) if mentally competent or, if incompetent, their legally authorized representatives  Any significant psychiatric problems, including acute confusional state (delirium), ongoing psychosis, or clinically significant depression Any current drug or alcohol abuse Any history of recurrent or unprovoked seizures Any prior movement disorder treatments that involved intracranial surgery or device implantation A history of neurostimulation intolerance in any area of the body Any significant medical condition that is likely to interfere with study procedures or likely to confound evaluation of study endpoints, including any terminal illness with survival <12 months Participation in another drug, device, or biologics trial concurrently or within the preceding 30 days. Any other trial participation should be approved by the Principal Investigators Pregnancy, breast-feeding, or lack of reliable contraception


eligible ages (years): 18.0-80.0,  All  Hereditary Spastic Paraplegia Age between 18 and 80 years Clinical diagnosis of Hereditary Spastic Paraplegia Ability to walk at least 10 meters: Assistive devices are permitted  Wheelchair bound patients Additional neurological symptoms that may significantly impact gait such as ataxia, polyneuropathy or dementia Fixed tendon contractures Antecedents of allergy or adverse reaction to botulinum toxin Pregnancy or breastfeeding condition Mental retardation Dementia


A 43-year-old woman visits her dermatologist for lesions on her neck. On examination, multiple lesions are seen. Each lesion is small soft, and pedunculated. The largest lesion is about 4 mm in diameter. The color of different lesions varies from flesh colored to slightly hyperpigmented.

eligible ages (years): 45.0-80.0,  All  Colon Cancer Polyps Patients who are 45 to 80 years old for routine screening colonoscopy  Patients with inflammatory bowel disease Patients with polyposis syndromes Pregnant women Patients over 350 pounds Patients with bright red blood per rectum Patients who have a contraindication to undergo outpatient colonoscopy, including patients on blood thinners, prior myocardial infarction (MI) in the last six months, history of congestive heart failure (CHF), history of arrhythmia, patients too weak to transfer themselves from a bed to a chair, or patients with severe constipation who would require a two day bowel preparation All subjects will undergo informed consent by the St. Luke’s institutional review board (IRB). Referred subjects will be asked if they are interested in the study and those responding affirmatively will be transferred to a recruiter to learn about the study and begin the consent process if interested


eligible ages (years): 18.0-999.0,  All  Polyps Patients: over 18 years of age, with clinical indication for colonoscopy who are considered by the endoscopist to be fit for the procedure Endoscopists who have started colonoscopy training on a recognised training rotation. Consultants who perform colonoscopy regularly  patients under 18 years, patients with previous colorectal surgery or known familial polyposis, patients unable to give informed consent, pregnant patients, patients for whom coloscope insertion was difficult or uncomfortable, patients whose colon is not sufficiently cleared of stool, those unwilling to participate


eligible ages (years): 18.0-999.0,  All  Colorectal Neoplasms Metastatic colorectal cancer Histologically or cytologically proven colorectal cancer Measurable disease on CT scan with at least one lesion >/= 2cm diameter (to allow adequate scout infusion imaging) Expected survival of at least 4 months ECOG performance status 0-2 Vital laboratory parameters should be within normal range including Neutrophils >/= 1.5 x 10^9/L Platelets >/= 150 x 10^9/L Serum bilirubin </= 34 micromol/L calculated creatinine clearance > 50 ml/min  Previous treatment with capecitabine Untreated active metastatic disease to the central nervous system (new or enlarging lesions on CT or MRI), or within 3 months of treatment (ie surgery or radiotherapy) for brain metastases Other serious illnesses, eg, serious infections requiring antibiotics, bleeding disorders Liver involvement with metastatic disease > 50% liver volume Chemotherapy, radiation therapy, or immunotherapy within 4 weeks before study entry (6 weeks for nitrosoureas) Previous external beam irradiation except if: (i) it was for standard adjuvant pelvic radiation for rectal cancer; (ii) it was for localised irradiation for skin cancer; or (iii) the sum total of all previous external beam irradiation port areas is not greater than 25% of the total red marrow Previous treatment with a monoclonal antibody or antibody fragment AND a positive huA33 HAHA titre Concomitant treatment with systemic corticosteroids. Topical or inhalational corticosteroids are permitted Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study Lack of availability of the patient for clinical and laboratory follow-up assessment


eligible ages (years): 18.0-999.0,  All  Skin Cancer Male or Female and over 18 years of age Patients undergoing an examination of their skin Patients with a lesion(s) in one of the five categories: basal cell carcinoma, squamous cell carcinoma, pre-cancer lesions, pigmented lesions, and benign lesions Patients whose lesion also warrants a biopsy Signed informed consent document  Patients with absence of skin lesion(s) in one of the five categories Patients whose identified lesion did not need a biopsy Patients who did not sign the informed consent and agree to participate


eligible ages (years): 0.0-999.0,  All  Skin Rash receiving bone marrow transplant -  not receiving other growth factors


eligible ages (years): 45.0-999.0,  All  Venous Insufficiency Aged 45 years and older CEAP classification: stage C4 (changes in skin and subcutaneous tissue secondary to CVDs)4a (pigmentation or eczema) 4b (lipodermatosclerosis or atrophie blanche) C5 (healed venous ulcers) Ankle brachial index (ABI) 0.9 3mm Hg 0 absence of peripheral arterial disease Intact skin sensation measured with 10 gram monofilament Intact thermal sensation measured with thermal sensory tester at lower leg skin and foot surfaces Agreement to wear compression garments such as wraps or stockings during waking hours Phone, e-mail, or mail accessible Working freezer  ABI < 0.8 mm Hg or > 1.3 mm Hg -presence of lower extremity arterial disease (reduces skin temperature) Active systemic or localized infections such as cellulitis (raises skin temperature) Autoimmune disorders that reduce blood flow such as Raynaud's phenomenon Body temperature > 37.6 degrees C (febrile state raises skin temperature) CEAP classification c6: active venous ulcer (cooling ulcerated skin might impair healing) Known peroneal nerve injury Impaired skin sensation Unable to detect light touch measured with a 10 gram monofilament at lower leg skin surfaces Unable to detect not/cold sensation measured with thermal sensory tester at lower leg skin surfaces Not wearing compression or not agreeing to wear compression wraps or stockings


eligible ages (years): 5.0-10.0,  All  Molluscum Contagiosum, Skin Disease Anyone aged 5-10 years with the clinical diagnosis of molluscum contagiosum  Anyone with immunosuppression including HIV or previous organ transplantation Anyone taking immunosuppressive medications Anyone who has previously received treatment with cantharidin Any female who has had her first menstrual period


eligible ages (years): 18.0-999.0,  All  Carcinoma, Advanced Metastatic Histologically confirmed advanced or metastatic non-curable solid tumor (if limited to a single lesion and not a candidate for curative surgery or radiation therapy) Completed ≥1 conventional therapy Clinically indicated surgery or procedure to collect available tumor in sufficient quantity ("golf ball size," pleural or ascites fluid may also be collected) for vaccine processing Subjects that have completed all acceptable therapies that are the current standard of care for their respective diseases Recovered from all toxicities related to prior therapies Subjects with brain metastases treated at least ≥2 months prior to enrollment, without related clinical symptoms and must have a stable neurological exam on the screening evaluation ≥1 measurable or evaluable lesion Age ≥18 years ECOG performance status (PS) 0-1 Normal organ and marrow function  Surgery involving general anesthesia, chemotherapy, radiotherapy, steroid therapy, or immunotherapy within 4 weeks prior to entering the study Patient must not have received any other investigational agents within 30 days prior to study entry Patients with known brain metastases unless treated and stable for ≥2 months Patients with mucinous adenocarcinoma Short term (<30 days) concurrent systemic steroids ≤ 0.125 mg/kg prednisone per day (maximum 10 mg/day) and bronchodilators (inhaled steroids) are permitted; other steroid regimens and/or immunosuppressives are excluded. Patients requiring steroids following previous CNS radiation for metastatic disease are excluded Prior splenectomy Prior malignancy (excluding nonmelanoma carcinomas of the skin) unless in remission for ≥2 years Kaposi's Sarcoma Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements Patients who are pregnant or nursing


eligible ages (years): 18.0-999.0,  All  Effects of Chemotherapy patients receiving docetaxel as mono or combination therapy patients with no nail disorders at the start of treatment life expectancy of at least 3 months  patients previously treated with taxane chemotherapy Raynaud's phenomenon distal metastases ungual pathology arteriopathy cold intolerance peripheral neuropathy of grade 2 or higher patients currently enrolled in clinical trials


eligible ages (years): 18.0-999.0,  All  Melanoma Patients or volunteers with or without a history of melanoma One or more palpable skin or subcutaneous lesions for which at least one of the following is true A tissue diagnosis has been made for the lesion(s) in question, by prior cytologic or histologic evaluation (Category A1) A tissue diagnosis will be obtained for the lesion(s) in question by cytologic or histologic evaluation (Category A2) A tissue diagnosis is not available, but a clinical diagnosis of melanoma or benign lesion is available with a high degree of confidence. Examples are hemangiomas, skin tags, seborrheic keratoses, dermatofibromas, lipomas, or growing pigmented skin lesions that are comparable to other cutaneous metastases of melanoma in the same patient (Category B) All patients must have the ability and willingness to give informed consent and must be age 18 years or older at the time of study entry  Known or suspected allergy to the adhesive skin markers or water-soluble ink used for the labeling of lesions Very fragile skin that may be susceptible to injury from adhesive markers Patients in whom there is a medical contraindication or potential problem in complying with the requirements of the protocol, in the opinion of the investigator


eligible ages (years): 18.0-999.0,  All  Skin Cancer Men and women over the age of 18 Skin lesion suspected to either BCC or SCC etc Patient was referred for biopsy diagnostic/therapeutic before hand, and regardless of confocal microscope examination, according to the clinical consideration of physician  Pregnant women Children


eligible ages (years): 18.0-75.0,  All  Basal Cell Carcinoma Study subjects must have had diagnosed at least one benign or malignant skin lesion Subject is from 18-75 years of age, inclusive Subject must sign and date all informed consent statements  Subject is exhibiting signs of a bacterial or viral infection, including fever Subject is unwilling to allow a biopsy of a malignant lesion for histological analysis


eligible ages (years): 18.0-999.0,  All  RECTAL NEOPLASMS Diagnosed with a large non-pedunculated rectal adenoma (sessile or flat) with a largest diameter of ≥2 cm (estimated by an opened resection snare of 20 or 30 mm) The lower and upper borders of the adenoma are located at ≥2 cm and ≤15 cm from the anal verge, respectively Biopsies of the lesion did not show malignant neoplastic tissue on histopathological evaluation; only lesions with low or high grade dysplasia are suitable for inclusion During flexible video endoscopy there are no signs of endoscopic suspicion for submucosal invasive cancer (Kudo pit pattern type V; excavated/depressed type morphology; fold convergence; or large smooth nodule >1 cm in a flat lesion) (33). In case of doubt, patients will undergo EUS as described at (2) In case doubt remains after flexible video endoscopy, endoscopic ultrasonography (EUS) of the rectal adenoma should invasion into the submucosal layer and pathological lymphadenopathy (lymph nodes >1 cm). When pathological lymph nodes are present, fine needle aspiration will be performed to lymph node metastasis (N+ disease) If not performed already, total colonoscopy will be done to detect and remove all synchronous colonic adenomas or cancers first. Cecal intubation must be confirmed by identification of the appendiceal orifice and ileocecal valve The general health condition of the patient permits general anesthesia (ASA classification I-III) Absence of non-correctable coagulopathy (international normalized ratio >1,5, or platelet count <90 × 109/l) Patient age of 18 years or older  Preoperative histologically detected malignancy Previous anorectal surgery Contraindications to general anaesthesia


eligible ages (years): 0.0-2.0,  All  Hemangioma Patients with ages up to 2 years Clinically diagnosed hemangioma, in proliferative or involutive phase, with relative indication for clinical treatment, as itemized lesion causing alteration of regional anatomy with no systemic or functional damage and with a diameter greater than 1 centimeter, or lesion causing aesthetic deformity, or lesion causing local repetitive complications such as ulceration, bleeding or local infection, or lesion causing partial damage of orifices, or lesion causing psychological compromise Absence of cardiopathy (normal physical examination, anamnesis, echocardiography, electrocardiography and thoracic radiography) Informed consent signed by responsible parties  Hemangioma with absolute indication for treatment, presenting a risk to function or life Patients with previous treatment for infantile hemangiomas Cardiac disease Pulmonary disease (asthma, bronchiolitis,bronchopulmonary dysplasias) Raynaud syndrome Pheochromocytoma Altered echocardiography, even if asymptomatic


eligible ages (years): 11.0-999.0,  All  Acanthosis Nigricans Hyperinsulinemia Spectroscopic Analysis Subjects must have an elevated fasting insulin level, suggesting they are in an insulin resistant state Subjects must carry a diagnosis of acanthosis nigricans, which will be verified by a Dermatologist before entry into the study. If necessary, a small 4mm punch biopsy may be taken to document dermatopathology consistent with acanthosis nigricans Subjects must be willing and able to undergo treatment with Metformin, including initial referral and follow up Agree to abide by the investigator's guidelines Be able to understand the requirements of the study, the risks involved and are able to sign the informed consent form Agree to follow and undergo all study-related procedures  Subjects with Type 1 Diabetes are excluded because of their naturally insulin-deficient, rather than hyper-insulinemic, states Women who are lactating, pregnant, or planning to become pregnant Any reason the investigator feels the patient should not participate in the study


eligible ages (years): 18.0-999.0,  All  Benign and Malignant Skin Neoplasms Patients with skin lesions undergoing biopsy for diagnosis  Patients with skin lesions which do not require biopsy for diagnosis


eligible ages (years): 20.0-85.0,  All  Lymphadenopathy Malignancy Patients with malignant cervical lymphadenopathie With US-FNA or US-CNB evaluation before  No ultrasound exam


eligible ages (years): 18.0-45.0,  All  Infant and Young Child Feeding Mothers with healthy children between 6 and 24 mo


eligible ages (years): 0.0-999.0,  All  Colonic Polyp Patients with pedunculated colorectal polyps, the heads of which were larger than 10mm and the stalk of which were large than 5 mm in diameter, were included  bleeding tendency poor preparation sessile polyp


eligible ages (years): 18.0-999.0,  All  Actinic Keratosis Male or female, age 18 years or older being seen in a dermatology clinic Informed consent of participation must be given by subject  Inability to complete all study questionnaires Subjects who are unable to read and write English


eligible ages (years): 20.0-35.0,  All  Acne Vulgaris Have Acne vulgaris, presenting at least inflammatory lesion on the face Body mass index between 18.0 and 30.0 kg/m2 (inclusive), and body weight not less than 50 kg (man) or 45 kg (woman) Blood pressure between 90 and 140 mmHg systolic (inclusive), and no higher than 90 mmHg diastolic Electrocardiogram (ECG) consistent with normal cardiac conduction and function Non-smoker Adequate contraception method for both men and women. If a woman, must have a negative pregnancy test Signed an informed consent document  History of or current clinically significant medical illness that the investigator considers should the participant or that could interfere with the interpretation of the study results Clinically significant abnormal values for hematology, biochemistry or urinalysis Clinically significant abnormal physical examination, vital signs or ECG Use of any prescription or nonprescription medication within 14 days before the study treatment History of drug or alcohol abuse within the past 5 years Drug allergy or drug hypersensitivity Blood donation, depending on the volume of blood collection Positive test for human immunodeficiency virus (HIV), hepatitis B or C, or syphilis Dermatological disease at application site Photosensitivity


eligible ages (years): 21.0-999.0,  All  Venous Disease Venous Vascular Diseases and Syndromes Venous Insufficiency Venous Ulcers aged 21 years or older CEAP Classification: Stage C4 (skin damage) and 5 (healed VLU) leg ulcer healed within past month with intact epithelium history of healed VLU within past 2 years ankle brachial index (ABI) 0.80 3 mmHG, absence of peripheral arterial disease intact skin sensation intact thermal sensation agreement to ear compression during waking hours phone, email or mail accessible  diagnosed arterial disease or ABI <0.80 or >1.3 mm Hg (blood flow to the skin is reduced in arterial disease and cooling could cause tissue ischemia) surgical procedures on leg in past 1 year (can affect venous circulation/cause edema) open leg/foot ulcers recent leg infection within past month (increased inflammation) impaired cognitive status (cannot perform procedures) chronic inflammatory and vascular conditions where blood flow of the skin may be impacted such as Lupus erythematosus, lymphedema, Raynaud's, rheumatoid arthritis, scleroderma, end stage renal disease, chronic obstructive pulmonary disease, chronic regional pain syndrome, multiple sclerosis, hypersensitivity to cold, or patients on chemotherapy


eligible ages (years): 18.0-999.0,  All  Actinic Keratosis Subjects must be competent to understand the nature of the trial and provide informed consent Subjects with 4 to 8 clinically typical, visible and discrete AKs within a contiguous 25 cm2 treatment area on the face or scalp Subject at least 18 years of age Female subjects must be of either Non-childbearing potential, i.e. post-menopausal or have a confirmed clinical history of sterility (e.g. the subject is without a uterus) or Childbearing potential, provided there is a confirmed negative urine pregnancy test prior to study treatment, to rule out pregnancy Female subjects of childbearing potential must be willing to use effective contraception  Location of the selected treatment area on any location other than the face or scalp within 5 cm of an incompletely healed wound within 10 cm of a suspected basal cell carcinoma (BCC) or SCC Prior treatment with PEP005 Gel on face or scalp Selected treatment area lesions that have atypical clinical appearance and/or recalcitrant disease History or evidence of skin conditions other than the trial indication that would interfere with evaluation of the trial medication Clinical diagnosis/history or evidence of any medical condition that would expose a subject to an undue risk of a significant AE or interfere with assessments of safety and efficacy


eligible ages (years): 18.0-999.0,  All  Postpolypectomy Bleeding Patients with one or more pedunculated polyps, the heads of which measured more than 1cm (regardless of the stalk thickness and length), and they were compared against the size of the biopsy forceps (6mm) and subsequently confirmed in the anatomical specimen Not to have any hemostatic alterations at the time the endoscopy was performed (confirmed by the usual blood tests taken before the procedure)  Patients younger than 18 years of age Patients with a platelet count of less than 50000, INR larger than 1.5 Patients who refused to give their informed consent


eligible ages (years): 18.0-50.0,  All  Non-palpable Breast Lesions Have had stereotactic or ultrasound-guided biopsy with marker placement Have a lesion or biopsy marker that is visible under ultrasound Have surgical target < 6 cm from the skin when lying supine Have a discreet surgical target Have a lesion in which the center/focal area is defined Be at least 18 years of age or older  Have a palpable lesion that does not require localization Require more than one localization needle for localization of the surgical target Have undergone previous open surgical biopsy or lumpectomy in the operative breast Have an implant in the operative breast Have a cardiac pacemaker or defibrillator device


eligible ages (years): 60.0-999.0,  All  Basal Cell Carcinoma (BCC) Patients over 60 years old BCC was determined with tissue diagnosis in the lower extremity One or more risk factor for surgical complication including: diabetes, venous insufficiency, obesity, peripheral vascular disease, lymphedema and long term steroids use  Patient unable to read, understand and sign the consent form


eligible ages (years): 18.0-999.0,  All  Wide-neck, Saccular Intracranial Aneurysms At least 18 years old A wide-neck intracranial saccular aneurysm with a neck ≥ 4mm or a dome to neck ratio <2 in the ICA from the cavernous segment to the carotid terminus (including the paraclinoid, ophthalmic, hypophyseal and posterior communicating segments) Life expectancy > 12 months Signed Informed Consent  Females who are pregnant or intend to become pregnant during the study. (Females of child-bearing potential must have a urinary pregnancy test within 7 days of enrollment) Extradural aneurysms Known multiple untreated cerebral aneurysms at study entry Recent history of subarachnoid hemorrhage, intracranial hemorrhage, or major surgery within one month of enrollment Admission platelet <50,000 or any known hemorrhagic diathesis, coagulation deficiency, or on oral anticoagulant therapy with an INR >3.0 Contraindication to angiography such as elevated creatinine or known allergy to angiographic contrast Contraindication to CT and/or MRI scans Known allergy to the metal component of the Penumbra Liberty Stent System Evidence of active infection (WBC >10x109 /L) Any medical conditions that will not allow the necessary follow-up for this study (e.g., pre-existing neurological or psychiatric diseases)


eligible ages (years): 18.0-999.0,  All  Non-melanocytic Skin Tumors Melanocytic Skin Tumors seborrhoeic warts nevi dermatofibroma basal cell carcinoma actinic keratosis squamous cell carcinoma Bowen's disease Merkel cell carcinoma malignant melanoma  employers of the Medical University of Vienna patients during compulsory military service patients with an appointed guardian


eligible ages (years): 0.0-999.0,  All  Clinically Atypical Pigmented Skin Lesion Cutaneous lesions examined with MelaFind must satisfy all of the following The lesion is pigmented (i.e., melanin, keratin, blood) The diameter of the pigmented area is not < 2 mm, and not > 22 mm The lesion is accessible to the MelaFind The patient, or a legally authorized representative, has consented to participate in the study and has signed the Informed Consent Form Cutaneous lesions that meet any of the following  will not be accepted The patient has a known allergy to isopropyl alcohol The lesion has been previously biopsied, excised, or traumatized The skin is not intact (e.g., open sores, ulcers, bleeding) The lesion is within 1 cm of the eye The lesion is on mucosal surfaces (e.g., lips, genitals) The lesion is on palmar hands The lesion is on plantar feet The lesion is on or under nails The lesion is located on or in an area of visible scarring


eligible ages (years): 18.0-80.0,  All  Colorectal Polyp pedunculated colorectal polyps larger than 2cm in diameter long-term antiplatelet therapy  presence of intraepithelial


eligible ages (years): 18.0-79.0,  All  Body Temperature Changes belong to ethnic groups requested  suffering any change in skin sensitivity, illness of an infectious nature or previously diagnosed diseases that respond negatively to the use of cold


eligible ages (years): 10.0-999.0,  All  Keloid Cicatrix, Hypertrophic Keloids, defined as excessive scar tissue raised above skin level and proliferating beyond the confines of the original lesion Hypertrophic scars1 older than 12 months and insensitive to other treatments. Keloids were distinguished from hypertrophic scars based on the clinical judgment of experienced plastic surgeons and on the age of the scar (>1yr) A period between previous treatment and IL cryotherapy covered a minimum of 12 weeks Patients with all Fitzpatrick17 skin types Patients older than 10 years of age  pregnancy diabetes mellitus


eligible ages (years): 18.0-45.0,  All  Postprandial Glycemia Age 18-45 Male No regular medication No participation in a drug trial or blood donation within 2 months Non-smoker Signs informed consent Body mass index 18.5-27 kg/m2 Fasting plasma cholesterol < 5.5 mmol/l Fasting plasma triacylglycerols < 2.6 mmol/l Fasting plasma glucose 4-6 mmol/l  Regular smoking Alcohol abuse Regular medication


eligible ages (years): 18.0-999.0,  All  Foreign Object Accidentally Left in Body During Surgical and Medical Care Healthy men and women Ages 18 or older -  Under 18 years of age Pregnant female or if female has not had a negative pregnancy test prior to the research scans


eligible ages (years): 10.0-999.0,  All  Keloid Cicatrix Hypertrophic Keloids, defined as excessive scar tissue raised above skin level and proliferating beyond the confines of the original lesion Hypertrophic scars1 older than 12 months and insensitive to other treatments. Keloids were distinguished from hypertrophic scars based on the clinical judgment of experienced plastic surgeons and on the age of the scar (>1yr) A period between previous treatment and IL cryotherapy covered a minimum of 12 weeks Patients with all Fitzpatrick17 skin types Patients older than 10 years of age  pregnancy diabetes mellitus


eligible ages (years): 35.0-70.0,  All  Skin Aging female gender age > 35 years old good general state of health woman who had already undergone Hyaluronic acid injections woman who have not applied any retinoid product in the last 3 months woman who are not in a recovery period after laser/peeling/acne treatment accepting to return to the centre for the planned visits accepting to follow the investigator's instructions during the entire study period agreeing to present at each study visit without make-up accepting to not change their habits regarding: food, physical activity, face cleansing and make-up use  Pregnancy (only for subjects not in menopause) lactation (only for subjects not in menopause) subjects not in menopause who do not use adequate contraceptive precautions in order to avoid pregnancies during the study subjects not in menopause who do not accept to perform the pregnancy test during the basal visit (T0), 6 and 12 weeks after the intradermal implant execution subjects participating to a similar test less than 3 months ago sensitivity to the test products or theirs ingredients subjects whose insufficient adhesion to the study protocol is foreseeable dermatitis presence of cutaneous disease on the tested area as lesions, scars, malformations clinical and significant skin condition on the test area (e.g. active eczema, dermatitis, psoriasis etc.)


eligible ages (years): 18.0-999.0,  All  External Genital Warts Adults at least 18 years old with at least two visible EGWs Subject must be in good general health as confirmed by the medical history Subject must be able to read, sign, and understand the informed consent Subject must be willing to forego any other treatments for his/her EGW lesions Subject is willing and able to participate in the study as an outpatient, making frequent visits to the study center during the treatment and follow-up periods and to comply with all study requirements including concomitant medication and other treatment restrictions If subject is a female of childbearing potential she must have a negative urine pregnancy test result prior to study treatment initiation and must agree to use an approved method of birth control while enrolled in the study  Subject with any evidence of herpes genitalis or any other current and/or recurrent genital or uncontrolled infection, including Human Immunodeficiency Virus, Hepatitis B or Hepatitis C Subject with an unstable medical condition as deemed by the clinical investigator Subject with any dermatologic disease in the treatment area that may be exacerbated by the treatment proposed or that might impair the evaluation of EGW lesions Subject who has previously been treated in an EGW clinical trial, had treatment of anogenital warts or had systemic intake of virostatics or immunosuppressive medication within 30 days prior to Baseline Visit Women who are pregnant, lactating, or planning to become pregnant during the study period Subject who have experienced a clinically important medical event within 90 days of the visit (e.g., stroke, myocardial infarction, etc) Subject who have active chemical dependency or alcoholism as assessed by the investigator Subject who have known allergies to any component of the study ointment Subject who have organ allograft, skin conditions that may interfere with study ointment, or having internal (vaginal or rectal) warts that have required treatment Subject who has received any of the following within 90 days prior to study treatment initiation


eligible ages (years): 18.0-80.0,  All  Bleeding Patients with pedunculated colorectal polyps, the heads of which were larger than 10mm and the stalk of which were large than 5 mm in diameter, were included  bleeding tendency, poor preparation, sessile polyp


eligible ages (years): 18.0-999.0,  All  Seborrheic Keratosis Subject is at least 18 years of age Subject has a clinical diagnosis of stable clinically typical seborrheic keratosis Subject has 4 appropriate seborrheic keratosis target lesions, as defined below (Section 5.4), on the trunk/extremities Have a clinically typical appearance Be treatment naïve Have a PLA of ≥2 (Section 6.1.2) Have a longest axis that is ≥7mm and ≤15mm (Section 6.1.3) Have a longest dimension perpendicular to the longest axis that is ≥7mm and ≤15mm (Section 6.1.3) Have a thickness that is ≤3mm Be a discrete lesion  Subject has clinically atypical and/or rapidly growing seborrheic keratosis lesions Subject has presence of multiple eruptive seborrheic keratosis lesions (Sign of Lesser-Trelat) Subject has a current systemic malignancy Subject has a history of keloid formation or hypertrophic scarring Subject has used any of the following systemic therapies within the specified period prior to Visit 1 Retinoids; 180 days Glucocorticosteroids; 28 days Anti-metabolites (e.g., methotrexate); 28 days Subject has used any of the following topical therapies within the specified period prior to Visit 1 on, or in a proximity to the target lesion, that in the investigator's opinion, interferes with the application of the study medication or the study assessments LASER, light (e.g., intense pulsed light [IPL], photo-dynamic therapy [PDT]) or other energy based therapy; 180 days


eligible ages (years): 0.0-999.0,  All  Melanoma All patients referred to the Dermatology Department, Lanarkshire Hospitals during a period to be defined for assessment of suspicious skin lesions (cutaneous moles) will be eligible for in the study. There are no age limits but patients under the age of 18 years will also have their subject to parental/guardian consent  There is no exclsion


eligible ages (years): 18.0-999.0,  All  Brain Micrometastases Adult patients with brain metastasis from any primary tumour receiving GKR All intracranial micro-metastases including lesions located in the cerebral hemispheres, thalamus, basal ganglia and cerebellum and excluding lesions located in the brain stem below the level of the superior colliculi Target volume < 0.14 cc3 and maximum diameter < 7 mm The subject consents to participate in the study  Inability to consent Younger than 18 years of age Lesions in the brainstem (below the level of the superior colliculi) are better treated with the 4 mm collimator and they will be excluded from the study Patients with more than 25 brain lesions suitable for randomisation will be excluded from the study Co-morbidity or previous treatment such as surgery, chemotherapy or WBRT is not to be considered as Pregnancy in the context of brain metastases is not a contraindication for GKR, and therefore it will not be considered as for this trial


eligible ages (years): 18.0-75.0,  All  Seborrheic Keratosis Subject is at least 18 years of age Subject has a Fitzpatrick skin type of 1-4 Subject has a clinical diagnosis of stable clinically typical seborrheic keratosis Subject has 1 appropriate seborrheic keratosis target lesion, as defined below (Section 5.4), on the face Have a clinically typical appearance Be treatment naïve Have a PLA of ≥2 (Section 6.1.2) Have a longest axis that is ≥7mm and ≤15mm (Section 5.4) Have a longest dimension perpendicular to the longest axis that is ≥7mm and ≤15mm (Section 5.4) Have a thickness that is ≤2mm  Subject has clinically atypical and/or rapidly growing seborrheic keratosis lesions Subject has presence of multiple eruptive seborrheic keratosis lesions (Sign of Lesser-Trelat) Subject has a current systemic malignancy Subject has a history of keloid formation or hypertrophic scarring Subject has used any of the following systemic therapies within the specified period prior to Visit 1 Retinoids; 180 days Glucocortico-steroids; 28 days Anti-metabolites (e.g., methotrexate); 28 days Subject has used any of the following topical therapies within the specified period prior to Visit 1 on, or in a proximity to the target lesion, which in the investigator's opinion, interferes with the application of the study medication or the study assessments LASER, light (e.g., intense pulsed light [IPL], photo-dynamic therapy [PDT]) or other energy based therapy; 180 days


eligible ages (years): 18.0-65.0,  All  Keratosis, Seborrheic Subjects are Caucasian or Asian Subjects who are between 18-65 year olds Subjects have flat or macular seborrheic keratosis on dorsum of the hands and wrists, extensor surfaces of the forearms. The diagnosis of flat seborrheic keratosis is confirmed by two clinical dermatologists using routine clinical examination and dermoscopy Subjects have Fitzpatrick skin type I-III Subjects are in good health Subjects have the willingness and the ability to understand and provide informed consent and communicate with the investigator  History of keloids or hypertrophic scars Pregnant or lactating or intends to become pregnant in the next 3 months Active skin disease or skin infection in the treatment area Previous history of lidocaine allergy History of methemoglobinemia Unable to understand the protocol or to give informed consent Any other condition that would, in the professional opinion of the investigator, potentially affect response or participation in the clinical study or would pose as an unacceptable risk to subject


eligible ages (years): 18.0-999.0,  All  Breast Neoplasm Have had stereotactic or ultrasound-guided biopsy with marker placement Have a lesion or biopsy marker that is visible under ultrasound Have a surgical target =< 6 cm from the skin when lying supine Have a discreet surgical target Have a lesion in which the center/focal area is defined Have the ability to understand and the willingness to sign a written informed consent document Eastern Cooperative Oncology Group (ECOG)/Karnofsky performance status will not be used as an criterion Ability to understand and the willingness to sign a written informed consent document  Require more than one localization needle for localization of the surgical target (bracket localization) Have undergone previous open surgical biopsy, lumpectomy, or mastectomy in the operative breast Have a prosthesis/implant in the operative breast Have a cardiac pacemaker or defibrillator device Be contraindicated for surgery Be pregnant


eligible ages (years): 20.0-999.0,  All  Colonic Polyp All those over the age of 20 years who agree informed consent and who have at least one polyp of eligible size (6-10 mm)  (1) patients taking anticoagulant therapy during the past 1 week of the procedure, (2) known coagulopathy, (3) history of liver cirrhosis, chronic kidney disease, malignancy, inflammatory bowel diseases or significant infectious disease, (4) American Society of Anesthesiology class III or more, and (5) pedunculated polyps and polyps with malignant feature


eligible ages (years): 12.0-999.0,  All  Acne Vulgaris Male or female at least 12 years of age and older Written and verbal informed consent must be obtained Subject must have a score of moderate or severe on the Evaluator's Global Severity assessment Pre-menses females and women of childbearing potential must have a negative urine pregnancy test at the screening and baseline visits Subjects must be willing to comply with study instructions and return to the clinic for required visits  Any dermatological conditions on the face that could interfere with clinical evaluations Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive Subjects with a facial beard or mustache that could interfere with the study assessments Subjects who are unable to communicate or cooperate with the Investigator Subjects with any underlying disease that the Investigator deems uncontrolled, and poses a concern for the subjects safety while participating in the study


eligible ages (years): 9.0-999.0,  All  Acne Vulgaris Male or female at least 9 years of age and older Written and verbal informed consent must be obtained Subject must have a score of moderate or severe on the Evaluator's Global Severity assessment at the screening and baseline visit Pre-menses females and women of childbearing potential must have a negative urine pregnancy test at screening and baseline visits Subjects must be willing to comply with study instructions and return to the clinic for required visits  Any dermatological conditions on the face that could interfere with clinical evaluations Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive Subjects with a facial beard or mustache that could interfere with the study assessments Subjects who are unable to communicate or cooperate with the Investigator Subjects with any underlying disease that the Investigator deems uncontrolled and poses a concern for the subject's safety while participating in the study


eligible ages (years): 18.0-60.0,  All  Dermatitis Healthy Subjects with Fitzpatrick Skin Types I, II or III  Subjects with visible skin disease, tattoos, skin condition, or abnormal skin color


A 44 yo male is brought to the emergency room after multiple bouts of vomiting that has a "coffee ground" appearance. His heart rate is 135 bpm and blood pressure is 70/40 mmHg. Physical exam findings include decreased mental status and cool extremities. He receives a rapid infusion of crystalloid solution followed by packed red blood cell transfusion and is admitted to the ICU for further care.

eligible ages (years): 18.0-999.0,  All  HIV Infections for Step 1 HIV infected Triple-class antiretroviral treatment, as determined by the site investigator and as defined by all of the following: a) exposure to 2 or more nucleotide reverse transcriptase inhibitors (NRTIs) for at least 3 months each; b) exposure to 2 or more non-boosted protease inhibitors (PIs) for at least 3 months each, or exposure to a dual PI regimen for at least 3 months; and c) exposure to at least 1 non-nucleotide reverse transcriptase inhibitor (NNRTI) for at least 3 months CD4 cell count of at least 50 cells/mm3 within 45 days prior to study entry Viral load of 2000 copies/ml or more within 45 days prior to study entry On current antiretroviral treatment regimen for at least 30 days prior to study entry. If current treatment includes abacavir, abacavir must be discontinued at least 30 days prior to study entry Willing to use acceptable methods of contraception  for Step 1 Pregnant or breastfeeding Allergy or sensitivity to the study drugs and their formulations Diabetes mellitus Cataracts or any measurable loss of vision due to lens opacity Best-corrected visual acuity worse than 20/200 Certain drugs or vaccines within 30 days prior to study entry History of any of the following: kidney disease; serious illness within 14 days prior to study entry; end organ cytomegalovirus infection; Kaposi's sarcoma; cataracts; active herpetic infection or peptic ulcer disease within 12 months; or malabsorption, severe chronic diarrhea, or inability to eat 1 or more meals a day because of chronic nausea, emesis, or abdominal/mouth and throat discomfort Current alcohol or drug abuse that would interfere with adherence to study requirements


eligible ages (years): 18.0-999.0,  All  Peptic Ulcer Hemorrhage Patients must be men or non-pregnant women at least 18 years of age Patients who present with a gastric or duodenal ulcer  Patients with ulcer appearance of clean base (non-oozing, non-spurting) or flat pigmented spot; adherent clots not removed by irrigation Patients presenting with active bleeding and/or NBVV at 2 or more separate sites Patients with any severe concomitant diseases, eg, end stage liver or renal disease, or unstable cardiovascular, pulmonary, renal, hepatic, or gastrointestinal diseases


eligible ages (years): 0.0-6.0,  All  Asphyxia Neonatorum Hypoxia Encephalopathy Seizures The infant will be assessed sequentially by A, B and C listed below A. Infants =>36 completed weeks gestation admitted to the NICU with at least one of the following Apgar score of =<5 at 10 minutes after birth Continued need for resuscitation, including endotracheal or mask ventilation, at 10 minutes after birth Acidosis within 60 minutes of birth (defined as any occurrence of umbilical cord, arterial or capillary pH <7.00) Base Deficit =>16 mmol/L in umbilical cord or any blood sample (arterial, venous or capillary) within 60 minutes of birth Infants that meet A will be assessed for whether they meet the neurological abnormality entry (B) by trained personnel B. Moderate to severe encephalopathy, consisting of altered state of consciousness (lethargy, stupor or coma) AND at least one of the following hypotonia abnormal reflexes including oculomotor or pupillary abnormalities  Infants expected to be > 6 hours of age at the time of randomisation Major congenital abnormalities, such as diaphragmatic hernia requiring ventilation, or congenital abnormalities suggestive of chromosomal anomaly or other syndromes that brain dysgenesis


eligible ages (years): 18.0-999.0,  All  Peptic Ulcer Male or female non-cirrhotic patients at least 18 years old suspected to bleed from PU Patients with haematemesis and/or hematochezia and/or melena which have been observed by a member of a clinical team (GP, hospital physician, nurse, ...) Either, documented signs of hypovolemia related to the current bleeding episode Or, occurrence of symptoms of hypovolemia  Treatment of the present bleeding episode with somatostatin or its analogues, vasoactive drugs, or endoscopic therapy Any treatment with PPIs (IV or per os) within the last 48 hours preceding randomisation Treatment (endotherapy or pharmacotherapy) for upper gastrointestinal ulcer bleeding in the last 30 days Deficient haemostasis (platelets < 40 x 109/l, international normalised ratio of the prothrombin time > 1.5 (or prothrombin time < 70%), or activated partial thromboplastin time > 40 seconds (or according to the normal ranges validated, from local lab)) Anticoagulant therapy (vitamin K antagonists or heparin including LMW heparins) Terminal stage illness in which endoscopy is contraindicated


eligible ages (years): 18.0-999.0,  All  Peptic Ulcer Patient has non-NSAID (non-steroidal anti-inflammatory drugs), non-Helicobacter pylori bleeding peptic ulcer Age > 18 years old Informed consent  Concommitant use of high dose steroid or warfarin New start on non-steroidal anti-inflammatory drugs or aspirin or COX2 inhibitors Renal failure (serum creatinine > 200umol/l) Previous gastric surgery Oesophagitis, esophageal varices Terminal illness or malignancy


eligible ages (years): 18.0-999.0,  All  Peptic Ulcer Hemorrhage Clean base ulcer with severe upper GIB (defined as melaena, hematochezia, hematemesis, and/or gross blood in NG lavage), and any one of the following SBP ≤ 90mmHg; P of ≥110 bpm; or orthostatic changes with SBP drops 20mmHg or P increases 20 bpm; or Transfusion of 2 or more units of packed red blood cells within 12 hrs of admission; or A documented HCT drop of at lest 6% from baseline Endoscopically confirmed bleeding from GU, DU, pyloric ulcer, or anastomotic ulcer Pt can either have primary or secondary acute UGI haemorrhage  Bleeding site from lesion other than GU, DU, pyloric or anastomotic ulcer there is more than one type of significant bleeding lesion Documented hx of cirrhosis / portal HT ESRF requiring any form of dialysis Expected or persistent (>24hrs) coagulopathy with INR> 1.5 Platelet count is under 50000/mm3 Aspirin User / Plavix [Clopidogrel] User If the ulcer is neoplastic Cannot obtained consent Age < 18 or is pregnant


eligible ages (years): 18.0-90.0,  All  Peptic Ulcer Hemorrhage all consecutive patients admitted for peptic ulcer bleeding (including bleeding anastomotic ulcers) with emergency endoscopy done in 24 hours after admission with Forrest type Ia, Ib, and IIa, IIb age 15 years Written consent available  ulcer bleeding not controlled in first endoscopy Bleeding from malignant ulcer or tumor Bleeding from Dieulafoy lesion/ angiodysplasia Bleeding from injection sclerotherapy ulcer Patient with ASA category 5


eligible ages (years): 16.0-999.0,  All  Peptic Ulcer Hemorrhage Age >16 , can obtain written consent Ulcers that require endoscopic therapy with SRH: Forrest I a, Ib, II a and II b  Moribund patients with terminal malignancy Pregnancy Intercurrent ulcer complication that prevents treatment and surgery becomes mandatory such as bulbar stenosis and ulcer perforation


eligible ages (years): 18.0-999.0,  All  Cardiac Arrest Male or female patients ≥ 18 years Witnessed out-of-hospital cardiac arrest of presumed cardiac origin in which the initial rhythm is ventricular fibrillation, ventricular tachycardia, pulseless electrical activity (PEA) or asystole First attempt at resuscitation (ACLS or CPR) by emergency medical personnel initiated within 15 minutes of collapse Restoration of spontaneous circulation (ROSC) within 60 minutes of collapse Time from restoration of spontaneous circulation to initiation of cooling is ≤ 6 hours Informed consent provided by authorized representative/family member  Temperature of less than 35C on admission Comatose or vegetative state prior to cardiac arrest Positive pregnancy test Purposeful response to verbal commands after ROSC and prior to initiation of hypothermia Evidence of hypotension (MAP<60) for more than 30 minutes after ROSC and prior to initiation of hypothermia Evidence of hypoxia (oxygen saturation<85% despite supplemental oxygen) for more than 15 minutes after ROSC and prior to initiation of hypothermia Terminal illness that preceded the arrest (life expenctancy < 1 year) Patients experiencing cardiogenic shock Patients continuing to experience refractory ventricular arrhythmias at the time of enrollment Patients receiving 2 or more high dose vasopressors


eligible ages (years): 18.0-999.0,  All  Shock Mean arterial pressure less than 70 mmHg or systolic pressure less than 100 mmHg persisting despite adequate fluid loading (in example with at least 1000 mL crystalloid or 500 ml colloid) unless central venous pressure (CVP) or pulmonary artery occluded pressure (PAOP) are elevated (e.g. CVP> 12 mmHg or PAOP > 14 mmHg)  Serious arrhythmia such as rapid atrial fibrillation (> 160/min) or ventricular tachycardia Brain death Open label administration of dopamine, norepinephrine, epinephrine or phenylephrine for more than 4hours


eligible ages (years): 15.0-999.0,  All  Shock, Traumatic Blunt or penetrating trauma Prehospital Systolic Blood Pressure (SBP) <= 70;OR Prehospital SBP 71-90 AND Hear Rate (HR) ≥108 years of age or older, or 50kg or more if age unknown  Known or suspected pregnancy Age younger than 15 or less than 50kg if age unknown Ongoing prehospital cardiopulmonary resuscitation (CPR) Administration of more than 2000cc crystalloid or any colloid or blood products Severe hypothermia (suspected Temperature less than 28 degrees celsius) Drowning or asphyxia due to hanging Burns Total Body Surface Area (TBSA) more than 20% Isolated penetrating injury to the head Inability to obtain prehospital intravenous access Time of call received at dispatch to study intervention greater than four hours


eligible ages (years): 18.0-90.0,  All  Peptic Ulcers Upper Gastrointestinal Bleeding Consecutive patients admitted for upper gastrointestinal bleeding secondary to peptic ulcers that have been successfully treated with endoscopic therapy  Variceal esophageal bleeding Concurrent PPI use Moribund patients


eligible ages (years): 18.0-79.0,  All  Hypothermia Heart Arrest Age between 18 and 79 years old Out-of-hospital cardiac arrest (OH-CA) due to a presumed cardiac etiology Delay between OH-CA and return of spontaneous circulation (ROSC) < 60 minutes Delay between ROSC and starting cooling < 240 minutes Patient not obeying verbal command after ROSC and prior to starting cooling Availability of the "CoolGard" device (ALSIUS product)  Do not reanimate order or terminal disease before Known pregnancy Clinical hemorrhagic syndrome or known coagulopathy Contra-indication to device usage (such as femoral venous access impossible) Hypothermia at admission < 30°C Etiology of OH-CA thought to be extra-cardiac (trauma, bleeding or anoxia) In hospital cardiac arrest Refractory shock (need for extra-corporeal life support)


eligible ages (years): 18.0-40.0,  All  Nausea Vomiting Cesarean Section Must be pregnant with a single baby Must be at term in their pregnancy (estimated gestational age of at least 38 weeks) Must be scheduled for an elective Cesarean section Must be between 60-70" tall Must be free of severe systemic disease (ASA class I or II)  Contraindication to spinal anesthesia Any allergy to any of the medications included in the study History of pregnancy-induced hypertension or preeclampsia History of preexisting hypertension Diabetes mellitus Hyperemesis gravidum Previous perioperative nausea and vomiting History of motion sickness Women carrying a fetus with a known abnormality will also be excluded from the study


eligible ages (years): 18.0-999.0,  All  Gastric Ulcer Duodenal Ulcer Daily intake of low-dose Aspirin (ASA) The subject must fulfill at least one of the following (a-e) Aged ≥65 years Aged ≥18 years and with a documented history of uncomplicated peptic ulcer(s) Aged ≥60 years and naïve to low-dose ASA (ie, treatment started within 1 month prior to randomization) Aged ≥60 years and with stable coronary artery disease Aged ≥60 years and with complaints of upper gastrointestinal (GI) symptoms that, as judged by the investigator, requires an Esophagogastroduodenoscopy (EGD) and with the finding of ≥5 gastric and/or duodenal erosions at the baseline endoscopy  Peptic ulcer(s) at baseline esophagogastroduodenoscopy (EGD) Reflux esophagitis Los Angeles (LA) classification grade C or D at baseline History of peptic ulcer complications such as clinically significant bleeding and/or perforation


eligible ages (years): 18.0-75.0,  All  Healthy Males 18 to 45 (Groups 1-9) or 55 to 75 (Group 10) years of age No clinically important abnormal physical, laboratory, ECG findings Normal (or abnormal but ncs) supine blood pressure (BP) and heart rate (HR)  Self or family history of cardiovascular or pulmonary disorder, coagulation or bleeding disorders or reasonable suspicion of vascular malformations eg cerebral haemorrhage, aneurysm or premature stroke Any autoimmune disease Previous allergic reaction to immunoglobulin Present, or history of, severe allergy, for example asthma or anaphylactic reactions or allergy requiring treatment Consumption of aspirin, other non-steroidal anti-inflammatory drugs or other drugs known to affect platelet function or any other aspect of coagulation within 14 days before drug administration Abnormal platelet function or clinically significant out of range values for any coagulation tests History of important bleeding episodes eg haematemesis, rectal bleeding, severe or recurrent epistaxis, haemoptysis, haematuria or intracranial haemorrhage Screening FVIII:C < 50%


eligible ages (years): 18.0-999.0,  All  Peptic Ulcer Perforation Patients surgically treated for benign peptic ulcer perforation  Age < 18 years Pregnant and breastfeeding women Malign ulcer perforation


eligible ages (years): 18.0-999.0,  All  Peptic Ulcer Hemorrhage Patients older than 18 Informed Consent signed Diagnosis of no variceal upper gastrointestinal bleeding secondary to a duodenal ulcer, erosive duodenitis or gastric ulcer Life expectancy longer than 6 months Able to attend further clinical controls Absence of the following  Previous eradication treatment Use of antibiotics 2 weeks prior to inclusion Need for Antisecretor treatment that cannot be stopped to perform the breath test Pregnancy or breastfeeding


eligible ages (years): 0.0-21.0,  All  Vomiting Syndrome Migraines Subjects age 0-21 years old with CVS (different phenotypes). Each patient's authorized legal guardian must understand the nature of the study and must provide written informed consent  Subjects age > 22 years old Vomiting is not due to CVS or other related condition


eligible ages (years): 18.0-80.0,  All  Peptic Ulcer Hemorrhage Patients were accepted for endoscopic therapy if a peptic ulcer with active bleeding, a non-bleeding visible vessel (NBVV) or an adherent blood clot at the ulcer base was observed within 24 hours of hospital admission  If patients were pregnant Did not obtain initial hemostasis with endoscopic injection of epinephrine Did not give written informed consent Had bleeding tendency (platelet count < 50×109/L, serum prothrombin < 30% of normal, or were taking anticoagulants), uremia


eligible ages (years): 18.0-85.0,  All  Fever Brain Hemorrhage Two or more days with core temperature ≥ 100.4F Approval of the patient's primary attending physician Need for core temperature measurement independent of the study Admission to the Neuro-ICU [intensive care unit] for an underlying condition  Evidence for an infectious cause of fever, such as pneumonia, bacteremia, CNS [central nervous system] infection or urinary tract infection Expected death from any cause Known sensitivity to the device History of pre-admission hypothalamic dysfunction or known temperature dysregulation Use of 2 or more vasopressor medications, since this may make a local skin reaction to the device more likely Hemodynamic instability


eligible ages (years): 12.0-65.0,  All  Scorpion Envenomation (All of the following) Patients of both sexes, in the age range of 12-65 years reporting to the PHC/ hospital within 48 hours of scorpion sting and associated with s/s of scorpion envenomation having composite score between 5 and 21 (as computed based on the below:) Grade Symptoms Sweating 0 Limited to the extremity of the sting site Minimal sweating all over the body, slight nasal secretions Generalized sweating with rigors and cold extremities Gen.profuse sweating,wetting of clothes and cold clammy skin Pulse rate 0 70  (Any of the following) Composite score less than 5 and greater than 21 Grade of 5 in any of the criterion Severe Pulmonary edema with oxygen saturation below 80% Severe scorpion envenomation with reporting time more than 2 days Any other serious medical disease which/treatment of which may confound the results e.g. cardiac diseases, diabetes, renal diseases etc Severe anaphylactic reaction to any of the study drugs Patient (or relative in case of child) not willing to participate


eligible ages (years): 18.0-999.0,  All  Non-Small Cell Lung Cancer Locally advanced or metastatic NSCLC (stage IIIB or IV) Patients who are not candidates for radical combined modality treatments or high-dose radiation therapy At least one measurable lesion according to Good performance status Adequate haematological, renal and liver function Written informed consent  Previous chemotherapy for NSCLC Brain metastasis History of cerebral haemorrhage, neurosurgery within 3 previous months or surgery within the past 6 months Indication for anticoagulant therapy, thrombolytic therapy or antiplatelet therapy for cardiovascular disease Concomitant therapy with an anti-angiogenesis agent Contra-indication for LMWH Life expectancy of < 3 months Serious concomitant systemic disease, uncontrolled arterial hypertension, active peptic ulcer or other condition which does not permit study treatment or follow-up required to comply with the study protocol


eligible ages (years): 18.0-999.0,  All  Non-variceal Upper Gastrointestinal Bleeding Gastrointestinal Ulcer Gastrointestinal Hemorrhage Patients admitted to the hospital or inpatients with an overt non-variceal upper GI bleed manifesting as hematemesis/coffee ground vomiting, melena, hematochezia, as well as other clinical/laboratory evidences of acute blood loss from the upper GI tract Evidence that an upper GI endoscopy was performed The complete medical record is available for study related hospitalization


eligible ages (years): 18.0-65.0,  All  Pain Male or female, more than 18 and less than 65 years of age Women using a method of contraception and with a negative pregnancy test before entering the study, or women who have been menopausal for at least 1 year Patients meeting one of the following Closed benign trauma of the motor system occurring within the last 24 hours Contusion of the motor system occurring within the last 24 hours Acute rheumatologic conditions (acute lower back pain, lumbar sciatica, cervicobrachial neuralgia) Abarticular rheumatism Requiring treatment with Bi-Profenid for 5 days With resting pain intensity measured on a numeric scale at baseline >or= 3 (before administration of any treatment) Receiving a prior medical examination suited to the study  Need for surgery Need for hospitalization Need for an analgesic other than step I at the baseline visit Need for treatment with another selective or non-selective NSAID (per os and/or topical), including aspirin, selective cyclo-oxygenase 2 inhibitors, corticosteroids or muscle relaxants at baseline and throughout the study Serious trauma: knee luxation, any fracture, ruptures such as Achilles tendon rupture Sprain treated with a cast Bursitis Local and/or general severe infection Pregnant or nursing women Hypersensitivity to ketoprofen or to any of the excipients of the product


eligible ages (years): 16.0-999.0,  All  Peptic Ulcer Hemorrhage Bleeding peptic ulcer: Among patients suspected to have upper GI bleeding based on hematemesis or melena, those with peptic ulcers(Forrest I, IIa and IIb) in whom active bleeding, non-bleeding visible vessels and fresh blood clots are observed on upper GI endoscopy performed within 24 hours after the hospitalization patients who achieved primary hemostasis with endoscopic hemostasis procedure via upper GI endoscopy  Patients who refuse endoscopic procedure Patients with complications from gastric ulcer that require operative treatment prior to upper GI endoscopic treatment(e.g., gastric outlet obstruction, peptic ulcer perforation) Pregnancy Patients with serious concurrent diseases such as malignant tumors or end-stage diseases History of previous gastrectomy or vagotomy Known hypersensitivity to proton pump inhibitors Elderly patients Epilepsy


eligible ages (years): 18.0-999.0,  All  Peptic Ulcer/Erosions upper GIB or dyspepsia due to peptic ulcers / erosions while receiving low-dose aspirin with a daily dose ranging from 80 mg to 320 mg endoscopy revealed a gastric or duodenal ulcers of 3 mm or more in diameter with unequivocal depth, or more than 5 erosions in the stomach or duodenum they required continuous low-dose aspirin for the secondary prevention of coronary heart disease, peripheral vascular disease and ischemic stroke or transient ischemic attacks years old or older  concurrent erosive or ulcerative esophagitis pyloric stenosis previous gastric or duodenal surgery other than oversewing of a perforation thrombocytopenia renal failure with estimated creatinine clearance less than 10 ml / min active cancer known allergic to aspirin, famotidine or pantoprazole pregnancy, lactation, child-bearing potential in the absence of contraception psychosomatic disorder planned co-prescription of nonsteriodal anti-inflammatory drugs corticosteriod, or anticoagulant


eligible ages (years): 40.0-90.0,  All  Peptic Ulcer Ulcer Complications Patients are eligible if they have received PCI for their stenotic coronary arteries and taken both aspirin and clopidogrel Patients who had a past history of PUD without complication, who have taken aspirin or clopidogrel before enrolling for their CV disease will be allowed to enroll  Patients are excluded if they have New York Heart Association class IV heart failure, if they had contraindications to antithrombotic or antiplatelet therapy, if they have clinical severe thrombocytopenia (platelet count< 80000/mm3), if they have previous disabling, or hemorrhagic stroke or intracranial hemorrhage, if they have severe and unstable conditions in hepatic, renal, and pulmonary disease, if they have unstable and progressive malignancy, if they have epigastralgia or have a positive occult blood in stool, if they have current or recent PUD and take PPI or histamine receptor-2 antagonist without proving healed ulcer by scopy, if they have received a surgical intervention due to PUD complication (bleeding, perforation, obstruction) in the past, if they have received a GP IIb/IIIa inhibitor fewer than 3 days before randomization


eligible ages (years): 18.0-999.0,  All  Peptic Ulcer aged more than 18 years undergo emergent endoscopy within 24 hours of presentation have peptic ulcers in the gastroesophageal junction, stomach, or duodenum high-risk stigmata of peptic ulcers: Forrest classification IA~IIB endoscopic hemostasis by thermocoagulation or clip placement  pregnant or lactating written informed consent not obtained initial endoscopic hemostasis fail bleeding tendency (platelet count < 50×109/L, prolonged prothrombin time for more than 3 seconds, or were taking anticoagulants) PPI use within 14 days of enrollment comorbid with severe hepatic or renal insufficiency (serum total bilirubin more than 5 mg/dL, serum creatinine more than 5 mg/dL, or under dialysis) bleeding gastric cancers


eligible ages (years): 18.0-75.0,  All  Advanced Esophageal Informed consent form signed before performing any of the study's specific procedures ECOG performance status 0-2 Age > 18 and < 75 Measurable disease by Response Evaluation in Solid Tumors (RECIST) greater than or equal to 1 cm (longest diameter) by spiral computed tomography (CT) scan and MRI or greater than or equal to 2 cm by other ordinary radiographic technique Histologically confirmed diagnosis of locally advanced esophageal Life expectancy of more than 3 months Use of an effective contraceptive method for patients of both sexes when there is a risk of conception and/or pregnancy No serious blood producing,abnormal function of heart,lung, liver, or kidney or immuno-deficiency Neutrophils ≥3×109/L, platelet count≥100×109/L and haemoglobin≥9g/dL ,Creatinine ≤ 1.5 x NUL  Previous radiotherapy or chemotherapy Pregnant or breast-feeding women Drug abuse, unhealthy drug/alcohol addiction,or virus (HIV) infection Evidence of distant metastasis Participation in other clinical trials Patients with aphthosis, complete obstruction, fistula or deep peptic ulcer in the esophagus, or haematemesis Uncontrolled psychiatric disease or seizure Patients not fit for the clinical trial judged by the investigators


eligible ages (years): 18.0-65.0,  All  Bleeding Marginal Ulcer patients status post laparoscopic RYGB surgery with active gastrointestinal hemorrhage secondary to marginal ulcer  bleeding marginal ulcers after other bariatric procedures staple-line bleeding after RYGB iron-deficiency anemia (chronic) secondary to non-actively bleeding marginal ulcer after RYGB other sources of GI bleeding different from marginal ulcer such as from staple-lines, complicated PUD, and other surgical and medical causes of GI hemorrhage missing records and/or unreachable patients with scant information for analysis


eligible ages (years): 18.0-65.0,  All  Ulcer Disease After Gastric Bypass Marginal Ulcer Perforated Marginal Ulcer Acutely Perforated Marginal Ulcer Laparoscopic repair of perforated marginal ulcer after RYGB  Perforated marginal ulcers after other bariatric procedures Repair by open approach Missing records and/or unreachable patients with scant information for analysis


eligible ages (years): 18.0-999.0,  All  Peptic Ulcer Patients presenting with clinical diagnosis of a perforated viscus who are scheduled to undergo surgical intervention Surgical candidate for endoscopic, laparoscopic, or open procedure Age > 21 Informed written consent  Prior gastric or duodenal surgery Prior total abdominal colectomy or transverse colectomy Prior omentectomy or omental flaps Known perforation site other than stomach or duodenum Patients with contra-indications for laparoscopy Patients with contraindications for endoscopy Upper gastrointestinal anatomy that would preclude endoscopic therapy Coagulopathy or thrombocytopenia Pregnant patients Patients <21 years of age


eligible ages (years): 18.0-65.0,  All  Postoperative Nausea and Vomiting ASA I or II female urologic, gynecologic and breast surgery patients undergoing scheduled same day procedures at LLUMC Heart and Surgical Hospital  age <18 or >65 severe hypertension,diabetes mellitus, significant hepatic or renal disease excessive blood loss sustained (>10 min)>20% from baseline drop in BP after treatment inability to follow protocol refusal to sign consent


eligible ages (years): 0.0-999.0,  All  Peptic Ulcer We plan to enroll 300 clopidogrel users without baseline gastroduodenal ulcer at initial endoscopy. The patients will be randomly assigned to receive either (1) esomeprazole (20 mg qd) plus clopidogrel or (2) clopidogrel treatment alone for 6 months  serious disease 2.refuse informed consent